The Emerging Hallmarks of Cancer Metabolism

Overview

Journal Cell Metab

Publisher Cell Press

Specialties Cell Biology
Endocrinology

Date 2016 Jan 16

PMID 26771115

Citations 2781

Authors

Natalya N Pavlova

Craig B Thompson

Affiliations

Soon will be listed here.

Abstract

Tumorigenesis is dependent on the reprogramming of cellular metabolism as both direct and indirect consequence of oncogenic mutations. A common feature of cancer cell metabolism is the ability to acquire necessary nutrients from a frequently nutrient-poor environment and utilize these nutrients to both maintain viability and build new biomass. The alterations in intracellular and extracellular metabolites that can accompany cancer-associated metabolic reprogramming have profound effects on gene expression, cellular differentiation, and the tumor microenvironment. In this Perspective, we have organized known cancer-associated metabolic changes into six hallmarks: (1) deregulated uptake of glucose and amino acids, (2) use of opportunistic modes of nutrient acquisition, (3) use of glycolysis/TCA cycle intermediates for biosynthesis and NADPH production, (4) increased demand for nitrogen, (5) alterations in metabolite-driven gene regulation, and (6) metabolic interactions with the microenvironment. While few tumors display all six hallmarks, most display several. The specific hallmarks exhibited by an individual tumor may ultimately contribute to better tumor classification and aid in directing treatment.

Citing Articles

Targeting metabolic reprogramming in glioblastoma as a new strategy to overcome therapy resistance.

DAprile S, Denaro S, Gervasi A, Vicario N, Parenti R Front Cell Dev Biol. 2025; 13:1535073.

PMID: 40078366 PMC: 11897528. DOI: 10.3389/fcell.2025.1535073.

Deciphering Colorectal Cancer-Hepatocyte Interactions: A Multiomics Platform for Interrogation of Metabolic Crosstalk in the Liver-Tumor Microenvironment.

Nelson A, Reese L, Rono E, Queathem E, Qiu Y, McCluskey B Int J Mol Sci. 2025; 26(5).

PMID: 40076609 PMC: 11900982. DOI: 10.3390/ijms26051976.

Metabolic expression profiling analysis reveals pyruvate-mediated EPHB2 upregulation promotes lymphatic metastasis in head and neck squamous cell carcinomas.

Miao J, Chen B, Zhang L, Lu Z, Wang R, Wang C J Transl Med. 2025; 23(1):316.

PMID: 40075431 PMC: 11899055. DOI: 10.1186/s12967-025-06305-9.

Potential biomarkers develop for predicting the prognosis of patients with esophageal squamous cell carcinoma after optimized chemoradiotherapy using serum metabolomics.

Yang J, Zhu Y, Zhou Y, Zhang J, Wei Y, Liu Y BMC Cancer. 2025; 25(1):438.

PMID: 40069698 PMC: 11900641. DOI: 10.1186/s12885-025-13866-x.

Glycogen drives tumour initiation and progression in lung adenocarcinoma.

Clarke H, Hawkinson T, Shedlock C, Medina T, Ribas R, Wu L Nat Metab. 2025; .

PMID: 40069440 DOI: 10.1038/s42255-025-01243-8.

References

Krajcovic M, Krishna S, Akkari L, Joyce J, Overholtzer M . mTOR regulates phagosome and entotic vacuole fission. Mol Biol Cell. 2013; 24(23):3736-45. PMC: 3842999. DOI: 10.1091/mbc.E13-07-0408. View

Wang R, Dillon C, Shi L, Milasta S, Carter R, Finkelstein D . The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity. 2011; 35(6):871-82. PMC: 3248798. DOI: 10.1016/j.immuni.2011.09.021. View

Lee J, Carrer A, Shah S, Snyder N, Wei S, Venneti S . Akt-dependent metabolic reprogramming regulates tumor cell histone acetylation. Cell Metab. 2014; 20(2):306-319. PMC: 4151270. DOI: 10.1016/j.cmet.2014.06.004. View

Sullivan L, Chandel N . Mitochondrial reactive oxygen species and cancer. Cancer Metab. 2015; 2:17. PMC: 4323058. DOI: 10.1186/2049-3002-2-17. View

Schug Z, Peck B, Jones D, Zhang Q, Grosskurth S, Alam I . Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell. 2015; 27(1):57-71. PMC: 4297291. DOI: 10.1016/j.ccell.2014.12.002. View

SAUER L, Stayman 3rd J, Dauchy R . Amino acid, glucose, and lactic acid utilization in vivo by rat tumors. Cancer Res. 1982; 42(10):4090-7. View

Blaschke K, Ebata K, Karimi M, Zepeda-Martinez J, Goyal P, Mahapatra S . Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature. 2013; 500(7461):222-6. PMC: 3893718. DOI: 10.1038/nature12362. View

MacDonald M, Warner T, Mertz R . High activity of mitochondrial glycerol phosphate dehydrogenase in insulinomas and carcinoid and other tumors of the amine precursor uptake decarboxylation system. Cancer Res. 1990; 50(22):7203-5. View

Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C . An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013; 340(6132):626-30. PMC: 3985613. DOI: 10.1126/science.1236062. View

10.

Janeway K, Kim S, Lodish M, Nose V, Rustin P, Gaal J . Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A. 2010; 108(1):314-8. PMC: 3017134. DOI: 10.1073/pnas.1009199108. View

11.

Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

12.

Yuneva M, Fan T, Allen T, Higashi R, Ferraris D, Tsukamoto T . The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab. 2012; 15(2):157-70. PMC: 3282107. DOI: 10.1016/j.cmet.2011.12.015. View

13.

Nicholson L, Smith P, Hiller L, Szlosarek P, Kimberley C, Sehouli J . Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer. Int J Cancer. 2009; 125(6):1454-63. DOI: 10.1002/ijc.24546. View

14.

Vacchelli E, Aranda F, Eggermont A, Sautes-Fridman C, Tartour E, Kennedy E . Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 2015; 3(10):e957994. PMC: 4292223. DOI: 10.4161/21624011.2014.957994. View

15.

Zhang C, Pan M, Li B, Wang L, Mo X, Chen Y . Choline and betaine intake is inversely associated with breast cancer risk: a two-stage case-control study in China. Cancer Sci. 2012; 104(2):250-8. PMC: 7657205. DOI: 10.1111/cas.12064. View

16.

Ying J, Rahbar M, Hallman D, Hernandez L, Spitz M, Forman M . Associations between dietary intake of choline and betaine and lung cancer risk. PLoS One. 2013; 8(2):e54561. PMC: 3562321. DOI: 10.1371/journal.pone.0054561. View

17.

Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S . Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011; 19(1):17-30. PMC: 3229304. DOI: 10.1016/j.ccr.2010.12.014. View

18.

Paschka P, Schlenk R, Gaidzik V, Habdank M, Kronke J, Bullinger L . IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010; 28(22):3636-43. DOI: 10.1200/JCO.2010.28.3762. View

19.

Spiro R . Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology. 2002; 12(4):43R-56R. DOI: 10.1093/glycob/12.4.43r. View

20.

Locasale J, Grassian A, Melman T, Lyssiotis C, Mattaini K, Bass A . Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet. 2011; 43(9):869-74. PMC: 3677549. DOI: 10.1038/ng.890. View